Javelin’s new patent will cover the major European Union market countries (G5) as well as an additional 20 member states of the European patent convention. This new patent is the European counterpart to Javelin’s US patent that was issued in September 2007.
Javelin believes that PMI-150 is optimized for use as a pain medication and may offer a safe, non-opioid alternative for the treatment of moderate-to-severe pain.
Martin Driscoll, CEO of Javelin, said: “The issuance of this European patent extends the term of commercial exclusivity for Javelin’s intranasal ketamine by almost a decade. This extension in the market exclusivity for intranasal ketamine should significantly enhance the potential value of the PMI-150 franchise and further bolster our global partnership discussions.”